Israel Englander Pds Biotechnology Corp Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Millennium Management LLC holds 234,209 shares of PDSB stock, worth $515,259. This represents 0.0% of its overall portfolio holdings.

Number of Shares

234,209

Previous 381,411 38.59%

Holding current value

$515,259

Previous $1.12 Million 19.96%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.93 - $4.23 $431,301 - $622,664	-147,202 Reduced 38.59%	234,209 $894,000
Q2 2024 Aug 14, 2024	BUY	$2.55 - $4.02 $972,598 - $1.53 Million	381,411 New	381,411 $1.12 Million
Q4 2023 Feb 14, 2024	BUY	$3.95 - $6.58 $50,232 - $83,677	12,717 New	12,717 $63,000
Q1 2023 May 15, 2023	BUY	$5.68 - $11.99 $823,236 - $1.74 Million	144,936 Added 32.11%	596,272 $3.67 Million
Q4 2022 Feb 14, 2023	BUY	$3.28 - $13.2 $1.48 Million - $5.96 Million	451,336 New	451,336 $5.96 Million
Q2 2022 Aug 15, 2022	BUY	$3.05 - $6.68 $459,015 - $1.01 Million	150,497 New	150,497 $549,000
Q1 2022 May 16, 2022	SELL	$4.78 - $8.43 $438,660 - $773,621	-91,770 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.76 - $14.35 $712,135 - $1.32 Million	91,770 New	91,770 $743,000
Q2 2021 Aug 16, 2021	SELL	$4.35 - $12.86 $91,924 - $271,757	-21,132 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$2.28 - $6.81 $48,180 - $143,908	21,132 New	21,132 $96,000
Q2 2020 Aug 14, 2020	SELL	$0.65 - $2.6 $43,702 - $174,811	-67,235 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$0.67 - $3.04 $45,047 - $204,394	67,235 New	67,235 $49,000

Others Institutions Holding PDSB

# of Institutions

Shares Held

4.32M

Call Options Held

253K

Put Options Held

70.4K

View Full List

About PDS Biotechnology Corp

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $62.6M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

More about PDSB

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account